title: Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
abstract: Prostate-specific antigen (PSA) is a protease able to bind to serum antiproteases as alpha 1 antichymotrypsin (ACT). Free PSA (FPSA) corresponds to the fraction of total PSA (TPSA) which is unbound to ACT. Specific detection of the FPSA seems to be a valuable tool in the distinction between prostatic cancer (PCa) and benign prostatic hyperplasia (BPH). Our aim was to evaluate retrospectively the FPSA/TPSA ratio in comparison to TPSA or FPSA determination, using two new immunoradiometric assays (PSA-RIACT and FPSA-RIACT, CIS bio international, Gif Sur Yvette, France) in the early diagnosis of PCa. 256 men, with TPSA levels between 0.7 and 44.7 ng/ml (median age = 69 years), including 164 sera obtained from patients with BPH and 92 sera from patients with untreated PCa were assayed. All diagnoses were histologically confirmed and patients tested before any adjuvant treatment. The evaluation of the median FPSA/TPSA ratio in the two groups showed significantly different values (BPH group: 24.2%, PCa group: 12.1%, P < 0.0001). By R.O.C. (Receiver-Operating-Characteristics) analysis, we show that the FPSA/TPSA ratio is the method of choice for discriminating BPH and PCa, since the area under curve is the greatest for the FPSA/TPSA ratio curve, as compared to the TPSA or FPSA curves (P < 0.0001). The best accuracy (number of true positive + true negative/total = 82.4%) was obtained with a FPSA/TPSA ratio < or = 15% with high odds ratio (20.5; confidence interval (CI): 11.2; 37.7). Of interest, similar results were also confirmed even in the subpopulation with serum TPSA levels between 2.5 and 10 ng/ml (161 patients including 99 BPH and 62 PCa). We thus confirm that combined serum measurement of FPSA and TPSA is of particular interest in the early diagnosis of PCa for patients with non-suspicious digital rectal examination and a TPSA value between 2.5 and 10 ng/ml. In those patients, biopsy should be reserved to the cases with FPSA/TPSA below 15%, which allows significant odds ratio (12.8; CI: 5.2; 31.4). Otherwise, to avoid the risk of missing any PCa, usual follow-up with combined TPSA and FPSA determination would be required with the same criteria of biopsy (i.e. FPSA/TPSA ratio < or = 15% when TPSA value is between 2.5 and 10 ng/ml; or TPSA > 10 ng/ml).
authors.affiliation: Nuclear Medicine Department, Saint-Louis Hospital, Paris, France.
authors.forename: M E
authors.initials: ME
authors.lastname: Toubert
authors.forename: J
authors.initials: J
authors.lastname: Guillet
authors.forename: M
authors.initials: M
authors.lastname: Chiron
authors.forename: P
authors.initials: P
authors.lastname: Meria
authors.forename: C
authors.initials: C
authors.lastname: Role
authors.forename: M H
authors.initials: MH
authors.lastname: Schlageter
authors.forename: H
authors.initials: H
authors.lastname: Francois
authors.forename: C
authors.initials: C
authors.lastname: Borschneck
authors.forename: F
authors.initials: F
authors.lastname: Nivelon
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
authors.forename: D
authors.initials: D
authors.lastname: Rastel
authors.forename: O
authors.initials: O
authors.lastname: Cussenot
authors.forename: P
authors.initials: P
authors.lastname: Teillac
authors.forename: A
authors.initials: A
authors.lastname: Le Duc
authors.forename: Y
authors.initials: Y
authors.lastname: Najean
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D003937:Diagnosis, Differential; D006801:Humans; D015592:Immunoradiometric Assay; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012372:ROC Curve; D012016:Reference Values; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen